SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF HOMOLOGOUS AD26 MOSAIC VECTOR VACCINE REGIMENS OR HETEROLOGOUS AD26 MOSAIC AND MVA MOSAIC VECTOR VACCINE REGIMENS WITH GLYCOPROTEIN 140 (GP140) FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVENTION: